Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
about
Aromatase Inhibitors for the adjuvant treatment of breast cancer in postmenopausal womenPreoperative chemotherapy for women with operable breast cancerPreoperative chemotherapy for women with operable breast cancerThe effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerReport on the 4th European Breast Cancer Conference, Hamburg, Germany, 16-20 March 2004Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast CancerThe evolution of the locoregional therapy of breast cancerNeoadjuvant therapy of early stage human epidermal growth factor receptor 2 positive breast cancer: latest evidence and clinical implicationsCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyNeoadjuvant therapy in the treatment of breast cancerExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerOncoplastic breast surgery: current strategiesFifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)Diffuse Optical Monitoring of the Neoadjuvant Breast Cancer Therapy.Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.Translating neoadjuvant therapy into survival benefits: one size does not fit all.Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.Image registration for quantitative parametric response mapping of cancer treatment responseSurgical management of early stage invasive breast cancer: a practice guideline.A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.Breast cancer (non-metastatic)Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancerThe E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancerBreast cancer local recurrence under the form of inflammatory carcinoma, treated with concurrent radiation and chemotherapy, a case reportBreast cancer: Actual methods of treatment and future trends.Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis.Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer.Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapyThe Role of Neoadjuvant Trials in Drug Development for Solid Tumors.Clinical practice guidelines for the care and treatment of breast cancer: mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer (summary of the 2002 update)Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womImportance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPhase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancerMRI in breast cancer therapy monitoringOncoplastic technique in breast conservative surgery for locally advanced breast cancer
P2860
Q24194371-4E059E9D-7E28-4145-B6C4-9C4BEF2B26AFQ24245281-89330ED4-3AE8-4495-9C84-BEF1553A6578Q24246444-FAF95461-CA2F-4C51-A1CB-C55AE342C43BQ24597847-61CD49CB-7240-42A4-B643-26C05FBEDE62Q24806223-6442524D-F0D3-47C4-A092-2339EEC48B8CQ26740393-30B8FA59-CBB0-47F0-BE31-8B3DFDBE9F02Q26992321-F97F529F-2B1F-431C-A778-D53BF87E157BQ27001729-36DFC03F-FC71-4025-AB71-874664C463C6Q27011658-A73289E3-2A6F-47AE-8EB8-25C12DC3DF61Q27694514-1010CD79-6CDB-4B54-BB7F-112126C9EFBBQ28066481-18E6E6AE-C708-4EF2-ADF7-24F8E07A433BQ28082147-D4753FD0-4F9F-4FEF-8C88-B3788F3CE0A1Q28270514-8A665E74-6F57-4AFF-B776-6A9BF494CF2BQ28710339-24860219-6EC6-4C45-A87D-0A492379CFE0Q30240816-F11EF0D5-0104-4C62-9B83-AA3C3B87B870Q30251738-DC76AC57-A1CD-472F-AC48-0877C972C5BFQ30315973-44C1CA95-0DC3-4B99-A448-CE82E25A6577Q30810432-A6A719ED-C3D5-4E04-A7E6-BBDD3623F3D4Q33218839-7C1EF2CE-2CA0-4A48-BAB0-F54B3BCDE135Q33267359-F1A74270-4399-4A02-B0DC-7D8CA8FF244CQ33369478-83983BBF-1F81-465D-9062-8E664EFD5E36Q33402700-F96CF487-4C49-47C1-9050-0355890A2CD7Q33446778-CA24136B-6B76-4CF8-916B-A62BF39BD685Q33620136-FA97EE2C-CB96-48AA-B3DC-40E702960740Q33630465-353DF277-8F8B-4D1B-96EC-8A567FDD5331Q33668173-A83A4AC9-6E2A-4CB5-9054-C97A27475B52Q33698446-C618A13B-0B2C-4B1A-BCE8-40DC81B68982Q33739585-91AC6E2F-7136-4236-A685-93E927C136E6Q33751728-3B1EDAA5-E0B2-4FCA-9838-D848BE9FE63CQ33751802-19B87945-A846-4788-AE78-C6DCCC52F6C7Q33778433-D0F1259A-A419-4B55-92B0-FFA5F97DB189Q33813431-ED931335-292E-4369-9DE4-AC68DBC247ABQ33873330-10206C85-230D-4846-B36C-E68FFF2E24CCQ33886353-0AAF1FFF-2085-4BB6-AEB2-146DDEDA3A44Q33889771-3F31B71A-6849-4433-B968-A7EAD33363C3Q33904763-DADF7C76-FAAB-4155-B072-8CB337EC1A9AQ33919243-9FCD1B34-DDB6-454E-B0FE-EBB270D05AABQ33922971-CD1A1620-C8C6-4B09-B0F5-BBA463BF8D41Q33938324-053F60F7-61D6-4A02-89E2-DD392B36FE6EQ33973166-621276CB-0079-4689-9E06-A30853B3F1F8
P2860
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Preoperative chemotherapy in p ...... eatment of Cancer trial 10902.
@en
type
label
Preoperative chemotherapy in p ...... eatment of Cancer trial 10902.
@en
prefLabel
Preoperative chemotherapy in p ...... eatment of Cancer trial 10902.
@en
P2093
P1476
Preoperative chemotherapy in p ...... eatment of Cancer trial 10902.
@en
P2093
C J van de Velde
C Vandervelden
J A van der Hage
J P Julien
L Duchateau
M Tubiana-Hulin
P304
P356
10.1200/JCO.2001.19.22.4224
P407
P577
2001-11-01T00:00:00Z